Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study
Neumora Therapeutics, Inc. has initiated a Phase 1 clinical study of NMRA-898, a M4 Positive Allosteric Modulator.
NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise, with potential best-in-class pharmacology.
- No convulsions were observed in pre-clinical studies conducted in multiple species, including rabbits.
Neumora plans to provide a comprehensive M4 franchise update by mid-2026.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company redefining neuroscience drug development.
Author summary: Neumora starts Phase 1 study of NMRA-898.